A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.

Condition(s) studied

Study summary

To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.

Eligibility

Primary outcome measure(s)

• CT-based radiomics analysis for benign and malignant tumor differentiation — within 1 month
  Histopathological diagnosis served as the gold standard, with tumors classified into: (1) Benign renal tumors: Including lipid-poor angiomyolipoma and renal oncocytoma; (2) Malignant renal tumors: Comprising clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma
• CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC) — within 1 month
  Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low grade ccRCC: Including WHO/ISUP grade 1-2 ccRCC; (2) high grade ccRCC: Including WHO/ISUP grade 3-4 ccRCC
• CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC) — within 1 month
  Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low T-stage RCC: Including T1-2 RCC; (2) high T-stage RCC: including T3-4 RCC

Trial sites (1)

More Second Xiangya Hospital of Central South University trials in China

Other trials for the same condition